Recent developments in 5lipoxygenase inhibitors

Bibliography

• FUNK D: Prostaglandins and leukotrienes: advances in eicosanoid biology. Science (2001) 294:1871–1875.
   PubMed Web of Science ®Google Scholar
• ••Description of LOX and COX pathway.
   Google Scholar
• SAMUELSSON B: Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science (1983) 220:568–575.
   PubMedGoogle Scholar
• LIMINGA M, OLIW E: cDNA cloning of 15-lipoxygenase Type 2 and 12-lipoxygenases of bovine corneal epithelium. Bioch. Biophys. Acta (1999) 1437:124–135.
   PubMedGoogle Scholar
• McGILL K, BUSSE W: Zileuton. Lancet (1996) 348:519–524.
   PubMed Web of Science ®Google Scholar
• LEFF A: Regulation of leukotrienes in the management of asthma: biology and clinical therapy. Ann. Rev Med. (2001) 52:1–14.
   PubMed Web of Science ®Google Scholar
• BUSSE W, McGILL A, HORWITZ J: Leukotriene pathway inhibitors in asthma and chronic obstructive pulmonary disease. Clio. Exp. Aller. (1999) 29:110–115.
   PubMedGoogle Scholar
• SHARON P, STENSO W: Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammation bowel disease. Gastroenterology (1984) 86:453–460.
   PubMed Web of Science ®Google Scholar
• KILFEATHER S: 5-lipoxygenase inhibitors for the treatment of COPD. Chest (2002) 121:197S–200S.
   Google Scholar
• GHOSH J, MYERS C: Arachidonic acid stimulates prostate cancer cell growth: critical role of 5-lipoxygenase. Biochem. Biophys. Res. Commun. (1997) 235:418–423.
   PubMed Web of Science ®Google Scholar
• ISRAEL E: Moderating the inflammation of asthma: inhibiting the production or the action of products of the 5-lipoxygenase pathway. Ann. Allergy (1994) 279–284.
   PubMedGoogle Scholar
• DIXON R, DIEHL R, OPAS E et al.: Requirement of a 5-lipoxygenase activating proteine for leukotriene synthesis. Nature (1990) 343:282–284.
   PubMed Web of Science ®Google Scholar
• MILLER D, GILLARD J, VICKERS P et al.: Identification and isolation of a membrane protein necessary for leukotriene production. Nature (1990) 343:278–281.
   PubMed Web of Science ®Google Scholar
• PETERS-GOLDEN M, BROCK T: Intracellular compartmentalization of leukotriene synthesis: unexpected nuclear secrets. FEBS Lett. (2001) 487:323–326.
   PubMed Web of Science ®Google Scholar
• HAMMARGERG T, PROVOST P, PERSSON B et al: The N-terminal domain of 5-lipoxygenase binds calcium and mediates calcium stimulation of enzyme activity. J. Biol. Chem. (2000) 275:38787–38793.
   PubMedGoogle Scholar
• CHEN X, FUNK C: The N-terminal '13-barrel' domain of 5-lipoxygenase is essential for nuclear membrane translocation. Biol. Chem. (2001) 276:811–818.
   Google Scholar
• YOUNG R: Inhibitors of the 5-lipoxygenase: a therapeutic potential yet to be fully realized? Eur. J. Med. Chem. (1999) 34:671–685.
   Google Scholar
• McMILLAN R, WALKER E: Designing therapeutically effective 5-lipoxygenase inhibitors. T1PS(1992) 13:323–330.
   Google Scholar
• •Classification of 5-LOX inhibitors.
   Google Scholar
• LEWIS R, AUSTEN K, SOBERMAN R: Leukotrienes and other products of the 5-lipoxygenase pathway. N Engl. I Med. (1990) 323:645–655.
   PubMed Web of Science ®Google Scholar
• LAM B, PENROSE I, FREEMAN G et al.: Expression cloning of a cDNA for human leukotriene C4 synthase, an integral membrane proteine conjugating reduced glutathione to leukotriene A. Proc. Natl. Acad. Sci. USA (1994) 91:7663–7667.
   PubMed Web of Science ®Google Scholar
• TATE S, MEISTER A: y-Glutamyl transpeptidase: catalytic, structural and functional aspects. MM. Cell. Biochem. (1981) 39:357–368.
   PubMed Web of Science ®Google Scholar
• LEE C, LEWIS R, COREY E et al: Conversion of leukotriene D4 to leukotriene E4 by a dipeptidase released from the specific granule of human polymorphonuclear leucocytes. Immunology (1983) 48:27–35.
   PubMedGoogle Scholar
• RADMARK O: The molecular biology and regulation of 5-lipoxygenase. Am. Resp. Grit. Care Med. (2000) 161:S11–S15.
   Google Scholar
• RIENDEAU D, FALGUEYRET J, GUAY J et al: Pseudoperoxidase activity of 5-lipoxygenase stimulated by potent benzofuranol and N-hydroxyurea inhibitors of the lipoxygenase reaction. Biochem. (1991) 274:287–292.
   Google Scholar
• OCHI K, YOSHIMOTO T, YAMAMOTO S. TANIGUCHI K, MIYAMOTO T: Arachidonate 5-lipoxygenase of guinea-pig peritoneal polymorphonuclear leukocytes. Activation by adenosine 5 -triphosphate. I Biol. Chem. (1983) 258:5754–5758.
   Google Scholar
• ROUZER C, KARGMAN S: Translocation of 5-lipoxygenase in human leukocytes challenged with ionophore A23187.1 Biol. Chem. (1988) 263:10980–10988.
   PubMed Web of Science ®Google Scholar
• YOKOMIZO T, IZUMI T, CHANG K et al: A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature (1997) 387:620–624.
   PubMed Web of Science ®Google Scholar
• HEISE C, O'DOWD B, FIGUEROA D et al.: Characterization of the human cysteinyl leukotriene 2 receptor. J. Biol. Chem. (2000) 275:30531–30536.
   Google Scholar
• LYNCH K, O'NEILL G, LIU Q et al.: Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature (1999) 399:789–793.
   Google Scholar
• GRONERT K, MARTINSSON T, RAVASI S et al.: Selectivity of recombinant human leukotriene D (4), leukotriene B(4) and lipoxin A(4) receptors with aspirin-triggered 15-epi-LXA (4) and regulation of vascular and inflammatory responses. Am. J. PathoL (2001) 158:3–9.
   PubMed Web of Science ®Google Scholar
• CAMP R, MALLET A, WOOLLARD P et al: The identification of hydroxy fatty acids in psoriatic skin. Prostaglandins (1983) 26:431–447.
   PubMedGoogle Scholar
• DAHLEN S, HEDQVIST P, HAMMARSTORM S et al: Leukotrienes are potent constrictor of human bronchi. Nature (1980) 228:484–486.
   Google Scholar
• TSUNODA H, ABE S, SAKUMA Y et al.:Involvement of leukotriene C4 in PAF-induced death in mice. Leukotrienes and Essential Fatty Acids (1990) 39:291–294.
   PubMedGoogle Scholar
• GOLDENBERG M, SUBERS E: The reactivity of rat isolated gastrointestinal tissues to leukotrienes. Eur. Pharmacol (1982) 78:463–466.
   PubMedGoogle Scholar
• MAGOUS R, BALI J, ROSSI J et al.: Lukotrienes stimulate acid secretion from isolated gastric parietal cells. Biochem. Brophy. Res. Com. (1983) 114:897–900.
   PubMedGoogle Scholar
• RIOUX N, CASTONGUAY A: Inhibitors of lipoxygenase: a new class of cancer chemopreventive agents. Carcinogenesis (1998) 19:1393–1400.
   PubMed Web of Science ®Google Scholar
• DE LEVAL X, JULEMONT F, DELARGE J et al.: New trends in dual 5-LOX/COX inhibition. Carr: Med. Chem. (2002) 9:941–962.
   Google Scholar
• HENNIG R, DING X, TONG W et al.: 5-lipoxygenase and leukotriene B(4) receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue. Am. J. Pathol (2002) 161:421–428.
   PubMedGoogle Scholar
• MYER C, GHOSH J: Lipoxygenase inhibition in prostate cancer. European Urology (1999) 35:395–398.
   PubMedGoogle Scholar
• SHUREIQI I, LIPPMAN S: Lipoxygenase modulation to reverse carcinogenesis. Cancer Res. (2001) 61:6307–6312.
   PubMed Web of Science ®Google Scholar
• FUJIMURA M, SAKAMOTO S, KAMINO Y et al: Effect of a leukotriene antagonist, ONO-1078, on bronchial hyper-responsiveness in patients with asthma. Respir. Med. (1993) 87:133–138.
   PubMed Web of Science ®Google Scholar
• NATHAN R, BERNSTEIN J, BIELORY L et al.: Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. Allergy Clin. (1998) 12:935–942.
   Google Scholar
• IHAKU D, CAMERON L, SUZUKI M et al.: Montelukast, a leukotriene receptor antagonist, inhibits the late airway response to antigen, airway eosinophilia and IL-5 expressing cells in Brown-Norway rats. Allergy Clio. (1999) 104:1075–1080.
   Google Scholar
• GOLDBERG B, STERN A: Production of superoxide anion during the oxidation of hemoglobin by menadione. Biochem. Biophys. Acta (1976) 437:628–632.
   PubMedGoogle Scholar
• GUINDON Y, GIRARD Y, MAYCOCK A et al: L-651,392: a novel, potent and selective 5-lipoxygenase inhibitor. Advances in Prostaglandin Thromboxane and Leukot. Res. (1987) 17A:554–557.
   PubMedGoogle Scholar
• BRUNEAU P, DELVARE C, EDWARDS M et al.: Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J. Med. Chem. (1991) 34:1028–1036.
   PubMed Web of Science ®Google Scholar
• BELANGER P, MAYCOCK A, GUINDON Y et al.: L-656,224 (7-chloro-2- [(4-methoxyphenyOmethyl] -3- methyl- 5-propy1-4-benzofuranol): a novel, selective, orally-active 5-lipoxygenase inhibitor. Can. .1 Physiol Pharinacol (1987) 65:2441–2448.
   Google Scholar
• TATERSON J, RANDALL R, REYNOLDS C et al.: Selective inhibition of arachidonate 5-lipoxygenase by novel acetohydroxamic acids: biochemical assessment in vitro and ex vivo. Br. Pharinacol (1988) 94:528–539.
   Google Scholar
• SUMMERS J, GUNN B, MARTIN J et al: Structure-activity analysis of a class of orally-active hydroxamic acid inhibitors of leukotriene biosynthesis. Med. Chem. (1988) 31:1960–1964.
   Google Scholar
• WENZEL S, KAMADA A: Zileuton: the first 5-lipoxygenase inhibitor for the treatment of asthma. Ann. Pharmacotherapy (1996) 30:858–864.
   PubMed Web of Science ®Google Scholar
• BOUSKA J: 6th Int. Conf. Inflamm. Res. Assoc. Sept. 20–24, White Haven (1992) 119. Abstract.
   Google Scholar
• BROOKS D, STEWART A, BASHA A et al.: 206th ACS Nat. Meeting, Aug 22–27, Chicago (1993) Abst. Medi. 41.
   Google Scholar
• SCOTT A, MALLOY E, WU W et al.: N-(5-substitued) thiophene-2-alkylsulfonamides as potent inhibitors of 5-lipoxygenase. Biorg. Med. Chem. (1997) 5:779–786.
   PubMedGoogle Scholar
• BIRD, BRUNEAU P, CRAWLEY G et al.:(Methoxyalkyl)thiazoles: a new series of potent, selective and orally-active 5-lipoxygenase inhibitors displaying high enantioselectivity. " Med. Chem. (1991) 34:2176–2186.
   Google Scholar
• •First description of non-redox 5-LOX inhibitors.
   Google Scholar
• CRAWLEY G, DOWELL R, EDWARDS P et al.: Methoxytetrahydropyrans. A new series of selective and orally potent 5-lipoxygenase inhibitors. Med. Chem. (1992) 35:2600–2609.
   Google Scholar
• BIRD T, BRUNEAU P, CRAWLEY G et al:(Methoxyalkyl)thiazoles: a new series of potent, selective and orally-active 5-lipoxygenase inhibitors displaying high enantioselectivity.f Med. Chem. (1991) 34:2176–21860.
   Google Scholar
• WALKER E: 13th Int. Symp. Med. Chem. Paris (1994) Abstract. 22.
   Google Scholar
• DUCHARME Y, BRIDEAU C, DUBE D et al.: Naphthalenic lignan lactones as selective, nonredox 5-lipoxygenase inhibitors. Synthesis and biological activity of (methoxyalkyl)thiazole and methoxytetrahydropyran hybrids. I Med. Chem. (1994) 37:512–518.
   Google Scholar
• MILLER D, GILLARD P, VICKERS S et al.: Identification and isolation of a membrane protein necessary for leukotriene production. Nature (1990) 343:278–281.
   PubMed Web of Science ®Google Scholar
• •Identification of the FLAP.
   Google Scholar
• MUSSER J, CHAKRABORTY U, SCIORTINO S et at.: Substituted arylmethyl phenyl ethers. 1. A novel series of 5-lipoxygenase inhibitors and leukotriene antagonists.' Med. Chem. (1987) 30:96–104.
   Google Scholar
• PRASIT P, BELLEY M, BLOUIN M et al.: A new class of leukotriene biosynthesis inhibitor: the development of MK-0591. .1 Lipid Med. (1993) 6:239–244.
   Google Scholar
• HAMILTON A, WATSON R, WYILE G et al.: Attenuation of early and late phase allergen-induced bronchoconstriction in asthmatic subjects by a 5-lipoxygenase activating protein antagonist, BAYx 1005. Thorax (1997) 52:348–354.
   PubMed Web of Science ®Google Scholar
• DEPRE M, VAN HECKEN A, VERBESSELT R et al.: Biochemical activity, pharmacokinetics and tolerability of tepoxalin, a cyclooxygenase/5-lipoxygenase inhibitor, in man. Int. I Clin. Pharmacol Res. (1996) 16:1–8.
   PubMedGoogle Scholar
• HARRIS R, BATT D, GALBRAITH W et al.: Topical anti-inflammatory activity of DuP 654, a 2-substituted 1-naphthol. Agents and Actions (1989) 27(Suppl.):297–299.
   Google Scholar
• CHIA Y, JONG H, SON K et al.: Effects of naturally-occurring prenylated flavonoids on enzymes metabolizing arachidonic acid: cyclooxygenases and lipoxygenases. Biochem. Pharmacol (2001) 62:1185–1191.
   PubMedGoogle Scholar